Without early IFN therapy, GC users had prevalence of PVS 3 times higher than nonusers, while GC users showed lower prevalence of PVS than nonusers among those receiving early IFN therapy (Fig. 2e, f). The gene discussed is IFNA1; the disease is perivascular space measurement.